Dr. Davison is a member of the Division of Anatomic Pathology and a member of the Gastrointestinal Pathology Center of Excellence. He is the clinical director of Quality Assurance for the Department of Pathology.
Clinical Expertise
Dr. Davison’s clinical expertise is in gastrointestinal pathology, including pathology of the pancreas, with a special interest in Barrett's esophagus, esophageal neoplasia, gastric pathology, appendiceal pathology, and quality improvement in pathology.
Specialties
Anatomic Pathology and Gastrointestinal Pathology
Dr. Davison’s main academic research interests focus on morphologic and molecular characterization of esophageal adenocarcinoma and risk stratification in patients with Barrett's esophagus with a view towards improving diagnosis and treatment.
View Dr. Davison's publications on PubMed
Landau MS, Hastings SM, Foxwell TJ, Luketich JD, Nason KS, Davison JM. Tumor budding is a pathologic predictor of lymph node metastasis in superficial esophageal adenocarcinoma. Modern Pathology. 2014 Dec;27(12):1578-89. PMID: 24762549
Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nature Genetics. 2015 Sep;47(9):1047-55. PMID: 26192918.
Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM*, Bass AJ*. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunology Research. 2015 Oct;3(10):1123-1129. PMID: 26081225. *Co-senior authorship.
Prichard JW, Davison JM, Campbell BB, Repa KA, Reese LM, Nguyen XM, et al. TissueCypher™: A systems biology approach to anatomic pathology. Journal of Pathology Informatics 2015;6:48. DOI: 10.4103/2153-3539.163987. PMID: 26430536
Davison JM, Landau MS, Luketich JD, McGrath KM, Foxwell TJ, Landsittel DP, Gibson MK, Nason KS. A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes. Clinical Gastroenterology and Hepatology. 2016 Mar;14(3):369-377. PMID: 26515637
Critchley-Thorne RJ, Duits LC, Prichard JW, Davison JM, Jobe BA, Campbell BB, Zhang Y, Repa KA, Reese LM, Li J, Diehl DL, Jhala NC, Ginsberg G, DeMarshall M, Foxwell T, Zaidi AH, Lansing Taylor D, Rustgi AK, Bergman JJ, Falk GW. A tissue systems pathology assay for high-risk Barrett’s esophagus. Cancer Epidemiology, Biomarkers and Prevention. 2016 Jun;25(6):958-68. PMID: 27197290.
Critchley-Thorne RJ, Davison JM, Prichard JW, Reese LM, Zhang Y, Repa K, Li J, Diehl DL, Jhala NC, Ginsberg GG, DeMarshall M, Foxwell T, Jobe BA, Zaidi AH, Duits LC, Bergman JJ, Rustgi A, Falk GW. A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus. Cancer Epidemiology, Biomarkers and Prevention. 2017 Feb;26(2):240-248. PMID: 27729357.
Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui UD, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison JM, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discovery. 2018 Jan;8(1):37-48. PMID: 28978556.
Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL*, Davison JM*, Bass AJ*. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology. 2018 Jul;155(1):156-167. PMID: 29608884 *co-senior authorship
Davison JM, Shah MB, Deitrick C, Chennat J, Fasanella KE, McGrath K. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices. Gastrointestinal Endoscopy. 2018 Nov;88(5):807-815. PMID: 29944863.
Sepulveda JL, Komissarova EV, Kongkarnka S, Friedman RA, Davison JM, Levy B, Bryk D, Jobanputra V, Del Portillo A, Falk GW, Sonett JR, Lightdale CJ, Abrams JA, Wang TC, Sepulveda AR. High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. International Journal of Cancer. 2019 Nov 15;145(10):2754-2766. PMID: 31001805.
Lowenthal BM, Nason KS, Pennathur A, Luketich JD, Pai RK, Davison JM, Ma C. Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma. Human Pathology. 2019 Dec;94:1-10. PMID: 31655170.
Davison JM, Goldblum J, Grewal US, McGrath K, Fasanella K, Deitrick C, DeWard AD, Bossart EA, Hayward SL, Zhang Y, Critchley-Thorne RJ, Thota PN. Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus. American Journal of Gastroenterology 2020 Jun;115(6):843-852. PMID: 32079863.
Tokuyama M, Geisler D, Deitrick C, Fasanella KE, Chennat JS, McGrath KM, Pai RK, Davison JM. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care. Histopathology 2020 Sep;77(3):481-491. PMID: 32431062.
Radu OM, Foxwell T, Cieply K, Navina S, Dacic S, Nason KS, Davison JM. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. American Journal of Clinical Pathology. 2012 Apr; 137 (4):583-94. PMID: 22431535.
Ong CA,** Shapiro J,** Nason KS,** Davison JM,** Liu X, Ross-Innes C, O’Donovan M, Dinjens WN, Biermann K, Shannon N, Worster S, Schulz LK, Luketich JD, Wijnhoven BP, Hardwick RH, Fitzgerald RC. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013 Mar 18. PMID: 23509313.**Co-first author paper. CA Ong, J Shapiro, KS Nason, and JM Davison contributed equally.
Batts KP, Ketover S, Krasinskas AM, Mitchell KA, Wilcox R, Westerhoff M, Rank J, Gibson J, Mattia AR, Davison JM, Naini BV, Dry SM, Yantiss RK. Appropriate use of special stains for identifying Helicobacter pylori: Recommendations from the Rodger C. Haggitt Gastrointestinal Pathology Society. American Journal of Surgical Pathology. 2013 Nov; 37 (11):e12-22. PMID: 24141174
Davison JM, Yee M, Krill-Burger JM, Lyons-Weiler MA, Kelly LA, Sciulli CM, Nason KS, Luketich JD, Michalopoulos GK, LaFramboise WA. The degree of segmental aneuploidy measured by total copy number abnormalities predicts survival and recurrence in superficial gastroesophageal adenocarcinoma. PLoS One. 2014; 9 (1):e79079. PMCID: PMC3894223. PMID: 24454681.
Davison JM, Choudry H, Ramalingam L, Zhu B, Pingpank J, Nikiforova M, Bartlett DL, Pai RK. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Modern Pathology. 2014 Nov;27(11):1521-39. PMID: 24633196
Davison JM, Hartman D, Singhi AD, Choudry HA, Pingpank JF, Ahrendt SA, Holtzman MP, Zureikat A, Zeh HJ, Ramalingam L, Nikiforova M, Bartlett DL, Pai RK. Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms. American Journal of Surgical Pathology. 2014 May; 38(5):583-92. PMID: 24618609.
Hasegawa SL, Davison JM, Rutten A, Fletcher JA, Fletcher CD. Primary cutaneous Ewing’s sarcoma: immunophenotypic and molecular cytogenetic evaluation of five cases. American Journal of Surgical Pathology. 1998 Mar; 22 (3):310-318. PMID: 9500772.
Davison JM, Morgan TW, Hsi BL, Xiao S, Fletcher JA. Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications. American Journal of Pathology. 1998 Nov; 153 (5):1401-1409. PMID: 9811331.
Davison JM, Akitake CM, Rhee JM, Goll MG, Gosse N, Baier H, Halpern ME, Leach SD, Parsons MJ. Transactivation from Gal4-VP16 transgenic insertions for tissue-specific cell labeling and ablation in zebrafish. Developmental Biology. 2007 Apr 15; 304 (2):811-824. PMCID: PMC3470427. PMID: 17335798.
Park SW, Davison JM, Rhee JM, Hruban RH, Maitra A, Leach SD. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. Gastroenterology. 2008 Mar 5; 134 (7):2080-2090. PMID: 18549880.